Stock Events

Stock Events

Lytix Biopharma AS 

kr10.35
3
-kr0.05-0.48% Thursday 14:25

Statistics

Day High
10.35
Day Low
10
52W High
11.9
52W Low
4.7
Volume
19,745
Avg. Volume
58,197
Mkt Cap
706.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

17FebExpected
Q4 2021
-0.42
-0.09
0.24
0.58
Expected EPS
N/A
Actual EPS
-0.4232

Financials

-759.68%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
33.03MRevenue
-250.89MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LYTIX.OL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. develops oncology drugs that directly compete with Lytix's cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb Company offers a range of immunotherapies in oncology, overlapping with Lytix's product pipeline.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG is a leader in oncology, with a broad portfolio that competes in the same therapeutic areas as Lytix.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has extensive investments in cancer treatment development, competing in the same market as Lytix Biopharma.
Novartis
NVS
Mkt Cap297.32B
Novartis AG focuses on innovative medicines in oncology, directly competing with Lytix's cancer therapies.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC has a strong focus on oncology, particularly in developing new cancer treatments that compete with Lytix.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. develops therapies for various cancer types, competing with Lytix's research and development in oncology.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is involved in the development of oncology drugs, which places them in direct competition with Lytix.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. works on innovative cancer treatments, competing in the same niche as Lytix.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division, develops cancer therapies that compete with Lytix's products.

About

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
Show more...
CEO
Dr. Oystein Rekdal Ph.D.
Employees
14
Country
NO
ISIN
NO0010405780

Listings

OL
NO
LYTIX.OL
F
DE
6BG.F

0 Comments

Share your thoughts

FAQ

What is Lytix Biopharma AS stock price today?▼
The current price of LYTIX.OL is kr10.35 NOK — it has decreased by -0.48% in the past 24 hours. Watch Lytix Biopharma AS stock price performance more closely on the chart.
What is Lytix Biopharma AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lytix Biopharma AS stocks are traded under the ticker LYTIX.OL.
Is Lytix Biopharma AS stock price growing?▼
LYTIX.OL stock has fallen by -0.48% compared to the previous week, the month change is a -1.43% fall, over the last year Lytix Biopharma AS has showed a +112.53% increase.
What is Lytix Biopharma AS market cap?▼
Today Lytix Biopharma AS has the market capitalization of 706.51M
What were Lytix Biopharma AS earnings last quarter?▼
LYTIX.OL earnings for the last quarter are -0.42 NOK per share, whereas the estimation was N/A NOK resulting in a N/A surprise. The estimated earnings for the next quarter are N/A NOK per share.
What is Lytix Biopharma AS revenue for the last year?▼
Lytix Biopharma AS revenue for the last year amounts to 33.03M NOK.
What is Lytix Biopharma AS net income for the last year?▼
LYTIX.OL net income for the last year is -250.89M NOK.
How many employees does Lytix Biopharma AS have?▼
As of April 10, 2026, the company has 14 employees.
In which sector is Lytix Biopharma AS located?▼
Lytix Biopharma AS operates in the Health Care sector.
When did Lytix Biopharma AS complete a stock split?▼
Lytix Biopharma AS has not had any recent stock splits.
Where is Lytix Biopharma AS headquartered?▼
Lytix Biopharma AS is headquartered in Oslo, NO.